Literature DB >> 20377648

The path to a paradigm shift in hemodialysis.

Melville H Hodge1.   

Abstract

About 1 out of 4 American conventional dialysis patients die in the first year and 3 out of 5 die within 5 years with no favorable trend in sight. Largely ignored in practice is the evidence accumulated over decades that longer, more frequent dialysis can immediately slash this grim result in half or more. Pierratos has called for a paradigm shift--a disruptive change--in dialysis practice from conventional treatment to daily nocturnal dialysis, performed at home, to realize this dramatic improvement. We examine here how such a paradigm shift might be brought about and suggest that changes in 3 perspectives must occur. First, new dialysis guidelines must be recast from the old goal of minimally adequate to a new goal of best possible. Second, the body of dialysis research must be interpreted through the lens of best possible patient survival and well being, and the near-impossibility of demonstrating dialysis survival advantage through randomized clinical trials must be acknowledged. Finally, dialysis modality must be seen as, most importantly, a survival and well-being choice, not merely a "Lifestyle" choice; hence, it must be the nondelegatable responsibility of the physician, not dialysis center personnel, to advise and prescribe. Many old perspectives, which might stand in the way of this sorely needed paradigm shift are also examined. These old perspectives make up a fabric of excuses that has delayed--and, if not discarded, will continue to delay--progress toward a survival and well-being outlook for dialysis patients just as favorable as might be achieved through kidney transplant.

Entities:  

Mesh:

Year:  2010        PMID: 20377648     DOI: 10.1111/j.1542-4758.2009.00425.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  1 in total

1.  Association between nutritional, inflammatory and oxidative status (NIOS) and risk of adverse outcomes in patients on haemodialysis (HD): the NIOS-HD prospective cohort study protocol.

Authors:  Sahar Foshati; Gholamreza Askari; Mohammad Bagherniya; Mojgan Mortazavi; Firouzeh Moeinzadeh; Shahram Taheri; Zahra Heidari; Mohammad Hossein Rouhani
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.